Top Story Today
$15 Billion Says the Science Beats the Politics
Bristol Myers Squibb is paying $600 million upfront (with up to $15.2 billion in total value) to partner with China's Hengrui Pharma on 13 preclinical drug programs across oncology, blood cancers, and immunology. None of these drugs have been tested in humans yet. It's like paying top dollar for 13 lottery tickets because you really trust the person selling them. The deal follows a similar GSK-Hengrui pact in July covering up to 12 medicines, and it lands while the BIOSECURE Act restricts federal contracts with certain Chinese biotech firms. BMS faces significant revenue at risk from patent cliffs by 2030, so the math apparently trumps the geopolitics.
Why it matters: China accounted for 32% of global biotech licensing deal value in Q1 2025, nearly doubling year-over-year. Western pharma is cannonballing into Chinese innovation to fill patent cliffs, and this deal crystallizes a tension that will define the industry for the next decade: the science wants to go east while the politics want it to stay home.
Read more →Clinical Breakthroughs
The Tiny Biotech That Cracked a Problem Big Pharma Couldn't
UK-based Enterprise Therapeutics just achieved a genuine scientific first: its inhaled ENaC blocker ETD001 improved lung function by 3.4 percentage points in cystic fibrosis patients (p=0.0053) in a Phase 2 trial. Every prior attempt at an inhaled ENaC blocker had failed. The drug targets the roughly 10% of CF patients who can't benefit from Vertex's Trikafta, and because it works regardless of mutation type, it could eventually layer on top of existing treatments for the other 90% too.
Read more →The First Drug That Destroys a Cancer Protein Instead of Blocking It
The FDA approved vepdegestrant (brand name Veppanu), the first-ever PROTAC therapy to reach patients. Developed by Arvinas and Pfizer, this daily pill doesn't just block the estrogen receptor in breast cancer; it tags it for destruction using the cell's own recycling machinery. In patients with ESR1-mutated tumors, it more than doubled time before disease progression compared to the old standard (5.0 vs. 2.1 months). It validates a technology platform two decades in the making.
Read more →Deals and Revivals
The Parkinson's Therapy That Came Back From the Dead
Novo Nordisk killed its entire cell therapy unit last October, leaving STEM-PD (one of the most advanced Parkinson's cell replacement therapies in history) without a home. Seven months later, Zuckerberg-backed AI startup Cellular Intelligence acquired global rights and plans to launch Phase 2 by year-end. The therapy transplants lab-grown dopamine neurons directly into the brain, targeting 12 million Parkinson's patients worldwide who have zero approved cell therapies.
Read more →Markets and Policy
One Pfizer Deal Sent European Pharma Stocks to Their Best Day Since 2008
European healthcare stocks surged after all 17 pharma companies targeted by the US government's Most-Favored-Nation pricing mandate signed voluntary agreements. After a year of apocalyptic drug pricing fears, analysts concluded the actual earnings impact looks more like a paper cut than a mortal wound, and the sector's policy-driven discount is compressing fast.
Read more →